Anti-Tuberculosis Drug Resistant Rates in Mycobacterium tuberculosis Isolated from Respiratory Specimens: A Multicenter Study in Korea.
- Author:
Jayoung KIM
1
;
Yeon Joon PARK
;
Nam Yong LEE
;
Chulhun L CHANG
;
Miae LEE
;
Jong Hee SHIN
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Anti-tuberculosis drug resistant rates; Extensive drug resistance; Multi-drug resistance; Mycobacterium tuberculosis
- MeSH: Dietary Sucrose; Drug Resistance; Drug Resistance, Multiple; Extensively Drug-Resistant Tuberculosis; Hospitals, University; Humans; Korea; Mycobacterium; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Tuberculosis; Tuberculosis, Pulmonary
- From:Annals of Clinical Microbiology 2013;16(1):1-7
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: We analyzed the prevalence of anti-tuberculosis drug resistance in Mycobacterium tuberculosis isolates from respiratory specimens of patients with newly diagnosed and previously treated tuberculosis. METHODS: From February 2010 to July 2010, a total of 542 M. tuberculosis clinical isolates were collected from pulmonary tuberculosis patients in six university hospitals distributed throughout Korea. We analyzed the results of anti-tuberculosis drug resistance tests according to treatment history and geographic location. RESULTS: Among the 542 isolates, 473 (87.3%) were from newly diagnosed cases and 69 (12.7%) were from previously treated cases. The rates of multi-drug resistance (MDR), fluoroquinolone (ofloxacin, levofloxacin, and moxifloxacin) resistance, and extensive drug resistance (XDR) were 3.8%, 1.1-1.5%, and 0%, respectively, in new cases, and 21.7%, 13.0-17.4%, and 4.3%, respectively, in previously treated cases. In the previously treated cases, the proportions of XDR-TB in MDR-TB were 20% (3/15). The resistance rates were variable according to geographic location. CONCLUSION: As the anti-tuberculosis drug resistance rates are much higher in newly diagnosed cases than in previously treated patients, efforts should be made to ensure that tuberculosis treatment is successful. In addition, before the selection of an anti-tuberculosis drug treatment for previously treated patients, the susceptibility test results, including to fluoroquinolone, should be verified.
